Objective-To determine whether the nocturnal fail in plasma adrenaline is a cause of nocturnal asthma.
Introduction
Measurements of airway calibre vary more from day to night in patients with asthma than in normal subjects, probably as a result of biological day-night rhythms superimposed in the airway inflammation and bronchial hyperresponsiveness that are characteristic of the disease.'2 A large day-night variation in pulmonary function occurs during unstable asthma and may lead to severe nocturnal wheezing or even death. In a previous study we showed that when parasympathetic efferent nerves are blocked with atropine at the time of nocturnal asthma brochodilatation occurs such that the fall in respiratory function at night is almost completely reversed, implying that increased parasympathetic efferent activity is an important cause of nocturnal asthma.3 This also implies, however, that other factors act in addition. These may include circadian rhythms of plasma adrenaline and cortisol,4 body temperature,5 sleep,6 a sympathetic nerves, or even dysfunction of non-adrenergic non-cholinergic bronchodilator nerves containing vasoinhibitory peptide. 7 Circadian changes in airway oedema may also be important. The role of plasma adrenaline in nocturnal asthma has been studied with two infusion rates of adrenaline at night in five asthmatic subjects. This study showed a reversal of the nocturnal fall in peak expiratory flow rate,4 but the infusion rates that were used produce a plasma adrenaline concentration at the upper end of the resting daytime physiological range8 and therefore the effect of adrenaline was almost certainly overestimated.
We investigated the role of plasma adrenaline in nocturnal asthma. In vitro studies have shown that, in addition to having a direct action on bronchial smooth muscle, adrenaline may modulate parasympathetic nervous activity through prejunctional P2 receptors,9 may influence the release of inflammatory mediators from mast cells,4 or may alter microvascular leak from blood vessels:'0
We measured the effect on peak expiratory flow rate of correcting the nocturnal fall in plasma adrenaline within the resting day/night range both before and after blocking parasympathetic efferent activity with atropine.3
Method
In this double blind placebo controlled crossover study we performed two experiments. In the first, 10 asthmatic subjects were studied, each with a diurnal of >20% for more inhaled ii2 agonists and anticholinergic drugs excluded litoring in the two for 10 hours before each study session. dmitted to hospital On study day 1 two cannulas were inserted before the ward routine the patient went to sleep. The patient was woken at 4 days. Oral theo-am, the pulse rate recorded, and blood taken for before admission, measuring plasma adrenaline concentration. The best -d throughout the of three peak flow manoeuvres was noted. 1) . Placebo infusions had no effect on either plasma adrenaline concentration, pulse rate, or peak flow rate. The infusion rate of adrenaline required to raise plasma 
Discussion
This study had investigated the dual role of parasympathetic efferent activity and plasma adrenaline in the pathogenesis ofnocturnal asthma. Parasympathetic blockade in this study caused a significant reversal ofthe nocturnal fall in peak flow rate as shown in our previous work.3 In the first arm of the study parasympathetic blockade reversed completely the nocturnal fall in peak flow rate, but the effect was not complete in the second arm.
Infusions ofadrenaline in a dose more than sufficient to reverse the nocturnal fall in plasma adrenaline both before and after parasympathetic blockade produced no significant increase in the peak flow rate at 4 am. Thus, although infusions of adrenaline in higher concentrations can cause bronchodilatation in both normal and asthmatic subjects (fig 2) ,'4'5 alterations of plasma adrenaline within the concentrations seen on a diurnal basis do not have any significant physiological effect on expiratory airflow limitation either by direct action on bronchial smooth muscle, modulation of vagal neurotransmission,8 mediator release from inflammatory cells,4 16 or by increasing microvascular leakage. 9 Our results agree with the earlier observation that a diurnal variation in pulmonary function can occur after adrenalectomy,'7 again confirming a lack of a primary role for adrenaline in nocturnal asthma. These observations do not detract from the therapeutic benefit of oral or inhaled 2 agonists in nocturnal asthma, when (as in this situation) pharmacological concentrations of the agonist are achieved at the receptor.
We conclude that the nocturnal fall in plasma adrenaline does not account for the other factor(s) that act with parasympathetic nervous activity to increase airflow limitation at night in asthma. The effect of the a sympathetic and non-adrenergic non-cholinergic nerves and also the study of diurnal variation of airway oedema and inflammatory mediators in nocturnal asthma may be of relevance for future research. 
